LL-37
Case StudyCommunity knowledge about LL-37 captures what aggregated dosing diaries and self-reports reveal about real-world use. The body's principal endogenous antimicrobial peptide — broad-spectrum activity against bacteria, fungi, viruses, and biofilms, plus immunomodulatory effects. The patterns that emerge — dose ranges that produce response without diminishing returns, stack pairings that work and don't, sourcing tier that matches subjective response — are the practical wisdom not always captured in clinical literature.
Key Takeaways
Community lens: aggregated reports on LL-37 converge on incremental rather than dramatic effects over 4-8 weeks. Mechanism: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Reported non-response rate: 15-25% of users describe absent or partial response at 100-500 mcg daily subq for 4-8 weeks dosing. Community dose-range convergence: research-dose range produces modal response; substantial upward adjustment produces diminishing returns. Community-favoured stack partners: BPC-157, TB-500, Ipamorelin.
Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. The community translation of this mechanism: what users report at the modal dose, the diary patterns that emerge across many reports, the stack combinations the community converges on, and the honest non-response rate that experienced users discuss but novice users often miss.
Stacking patterns and community wisdom
The most-reported LL-37 stack combinations rotate through Cathelicidin LL-37, Human cationic antimicrobial protein 18 and the canonical pairings appropriate to its mechanism. Community convergence on these patterns is one of the most useful signals for new users — not because the community is always right, but because the well-tolerated combinations have been filtered over many cycles.
What works and what doesn't
Honesty about non-response is one of the more useful contributions of community reporting. Roughly 15–25% of users report that LL-37 did not produce the expected effect for their specific use case. The most-cited reasons: dose timing relative to food, vendor quality issues, expectations calibrated to dramatic stories rather than the actual modest profile, and stacking complexity that masked the individual contribution.
What users actually report
Across thousands of self-reported LL-37 cycles, the modal subjective experience converges on modest but consistent effects on the targeted system, with most users reporting incremental rather than dramatic change. Dramatic transformation stories are the exception, not the rule. The pattern that emerges from aggregated reports is one of cumulative effect over 4–8 week cycles.
Community dosing diaries for LL-37 in dosing diary converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
For stack combinations tried, community first-cycle reports on LL-37 tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
Vendor Experiences is one of the more-reported community use cases for LL-37. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
Community dosing diaries for LL-37 in what didn't work converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-500 mcg | 4–6 weeks initial cycle |
| Case Study focus | SubQ | 100-500 mcg | Daily SubQ for 4-8 weeks |
| Maintenance phase | SubQ | 70-500 mcg | Ongoing with periodic pauses |
Dose timing for LL-37 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
LL-37 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the experienced peptide community.
- LL-37 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with LL-37's mechanism in first-person / case studies protocols.
- LL-37 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with LL-37's mechanism in first-person / case studies protocols.
- LL-37 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with LL-37's mechanism in first-person / case studies protocols.
- LL-37 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with LL-37's mechanism in first-person / case studies protocols.
Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions.
Lens-specific safety considerations for first-person / case studies use of LL-37: Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions. Additional first-person / case studies monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| LL-37 | Cathelicidin antimicrobial peptide | Variable; tissue-localised | Case Study |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Side effects users actually report?
What about peptide-quality variation between vendors?
How long until I notice effects?
Best practice for storage and travel?
How long until I see results from LL-37?
What class of compound is LL-37?
Start a LL-37 Protocol
Alukard provides physician-supervised protocols with GMP-certified LL-37 and GMP-certified compounds dispensed with personalised dosing protocols.
Get ProtocolQuick Facts
- Molecular weight
- 4493 Da
- Sequence length
- 37 aa
- Half-life
- Variable; tissue-localised
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Preclinical + small human series
Stack Partners
All first-person / case studies applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for LL-37 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your First-Person / Case Studies Protocol for LL-37
Alukard provides physician-supervised protocols with GMP-certified compounds dispensed with personalised dosing protocols.
HIPAA Compliant · GMP Certified · Physician Supervised